Presentation at the Global Investor Network

We will be introducing Pleco at the Global Investor Forum on 18th March 2021. Please register to join the presentation of our CEO Ivo Timmermans at the pitching session from 4.15 – 5.30 pm CET. The Global Investor Forum is..

Read more..

Pleco Therapeutics receives funding from Oost NL

NIJMEGEN, March 1st, 2021 – Pleco Therapeutics has been granted financial support by the ION+ Innovation fund for small and medium-sized businesses in the province of Gelderland. The fund is managed by Oost NL, backed by the EU and the..

Read more..

Best wishes for 2021

We hope you and your family had a pleasant Holiday season. We wish to thank you for your support during a difficult 2020 and extend our best wishes for the New Year. At Pleco, we had to overcome some obstacles..

Read more..

Blood Cancer Awareness Month

Due to the rarity of the disease, data are lacking on the relationships between AML and most risk factors, and strong connections have not been made through epidemiological studies. Pleco Therapeutics is proud to be focusing on a disease where..

Read more..

Blood Cancer Awareness Month

Secondary Acute Myeloid Leukaemia occurs more frequently in the elderly AML population than in younger patients and is typically more difficult to treat as it is less responsive to standard chemotherapies...

Read more..

Blood Cancer Awareness Month

The cause of AML is unknown; however, several risk factors have been associated with increased chance of developing AML, including, age, male sex, a history of smoking, and exposure to high doses of radiation and cytotoxic chemicals...

Read more..